OOna Therapeutics — Series B · €74.2M
IRB Barcelona spin-out closed an oversubscribed €74.2M Series B co-led by Columbus and Mérieux to take its first-in-class antibody-drug conjugates against treatment-resistant breast and colorectal cancers into the clinic.
LeadColumbus Venture Partners, Mérieux Equity Partners
RoundSeries B
Announced4 Jun 2026
CityBarcelona
SectorHealthtech & Bio
Source
W
G
B
W
G
B
The company
Investors 11
CColumbus Venture Partners
columbusvp.com
M
Mérieux Equity Partners
AAlta Life Sciences
altals.com
AAsabys Partners
asabys.com
B
Bpifrance
CCDTI Innvierte
cdti.es
Profile: Centro para el Desarrollo Tecnológico y la Innovación
CCOFIDES
www.cofides.es
F
Fund+
FFundPlus
K
Korys
YYsios Capital
ysioscapital.com